Evidence map›Paper›PMID 26230842›Full record

ArticlePloS one2015

High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer.

Nathaniel Melling, Levon Harutyunyan, Claudia Hube-Magg, Martina Kluth, Ronald Simon, Patrick Lebok, Sarah Minner, Maria Christina Tsourlakis, Christina Koop, Markus Graefen and 9 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Nathaniel MellingInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany; General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Germany.
Levon HarutyunyanInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
Claudia Hube-MaggInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
Martina KluthInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
Ronald SimonInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
Patrick LebokInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
Sarah MinnerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
Maria Christina TsourlakisInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
Christina KoopInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
Markus GraefenMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Germany.
Meike AdamMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Germany.
Alexander HaeseMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Germany.
Corinna WittmerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
Stefan SteurerInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
Jakob IzbickiGeneral, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Germany.
Guido SauterInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
Waldemar WilczakInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
Thorsten SchlommMartini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Germany; Department of Urology, Section for translational Prostate Cancer Research, University Medical Center Hamburg-Eppendorf, Germany.
Till KrechInstitute of Pathology, University Medical Center Hamburg-Eppendorf, Germany.
University Medical Center Hamburg-Eppendorf · DEUniversität Hamburg · DEMartini-Klinik · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hook microtubule-tethering protein 3 (HOOK3) is an adaptor protein for microtubule-dependent intracellular vesicle and protein trafficking. In order to assess the role of HOOK3 in prostate cancer we analyzed HOOK3 expression by immunohistochemistry on a TMA containing more than 12,400 prostate cancers. Results were compared to tumor phenotype and PSA recurrence as well as aberrations possibly defining relevant molecular subtypes such as ERG status and deletions of 3p13, 5q21, 6q15 and PTEN. HOOK3 immunostaining was negative in normal luminal cells of prostate epithelium, whereas 53.3% of 10,572 interpretable cancers showed HOOK3 expression, which was considered low in 36.4% and high in 16.9% of cases. High-level HOOK3 expression was linked to advanced tumor stage, high Gleason score, high proliferation index, positive lymph node stage, and PSA recurrence (p<0.0001 each). The prognostic role of HOOK3 expression was independent of established clinico-pathological parameters both in preoperative and postoperative settings. Comparisons with molecular features were performed to draw conclusions on the potential function of HOOK3 in the prostate. A strong association with all examined deletions is consistent with a role of HOOK3 for maintaining genomic integrity by contributing to proper centrosome assembly. Finding HOOK3 expression in 74% of ERG positive but in only 38% of ERG negative cancers (p<0.0001) further suggests functional interactions between these genes. In conclusion, the results of our study identify HOOK3 as a strong candidate prognostic marker with a possible role in maintaining genomic integrity in prostate cancer, which may have potential for inclusion into clinical routine assays.

Indexed as

Genomic InstabilityAgedBiomarkers, TumorCell ProliferationHumansMaleMicrotubule-Associated ProteinsMiddle AgedOncogene Proteins, FusionPrognosisProstateProstate-Specific AntigenProstatic NeoplasmsBiomarkers, Tumorhook3 protein, humanMicrotubule-Associated ProteinsOncogene Proteins, FusionProstate-Specific AntigenTMPRSS2-ERG fusion protein, human

Identifiers

PMID26230842
PMCPMC4521853
OpenAlexW2157456012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.